BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Phase 1

Completed

Conditions: Heart Failure With Reduced Ejection Fraction
Dilated Cardiomyopathy

Interventions: Drug: MYK-491
Drug: Placebo

First Posted Date: 2018-02-27

Last Posted Date: 2023-02-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 52

Registration Number: NCT03447990

Locations: 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

and more 14 locations

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Phase 1

Completed

Conditions: Nonalcoholic Fatty Liver Disease
Hepatic Cirrhosis
Liver Fibrosis
Nonalcoholic Steatohepatitis

Interventions: Drug: BMS-986036

First Posted Date: 2018-02-26

Last Posted Date: 2020-03-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT03445208

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Biological: BMS-986258
Biological: Nivolumab
Drug: rHuPH20

First Posted Date: 2018-02-26

Last Posted Date: 2025-01-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 92

Registration Number: NCT03446040

Locations: 🇺🇸
Local Institution - 0012, Lebanon, New Hampshire, United States
🇺🇸
Local Institution - 0007, Aurora, Colorado, United States
🇺🇸
Local Institution - 0016, Cincinnati, Ohio, United States

and more 13 locations

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: BMS-986299
Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2018-02-23

Last Posted Date: 2022-05-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 82

Registration Number: NCT03444753

Locations: 🇺🇸
Local Institution, Pittsburgh, Pennsylvania, United States
🇺🇸
Local Institution - 0003, La Jolla, California, United States
🇺🇸
University of California Davis Medical Center, Sacramento, California, United States

and more 2 locations

Study of Nivolumab for Advanced Cancers in India

Phase 4

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Kidney Cancer
Kidney Neoplasms
Renal Cancer
Renal Neoplasms

Interventions: Drug: Nivolumab

First Posted Date: 2018-02-23

Last Posted Date: 2020-12-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT03444766

Locations: 🇮🇳
Local Institution, Vellore, India

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Completed

Conditions: Melanoma

Interventions: Other: Non-Interventional

First Posted Date: 2018-02-19

Last Posted Date: 2018-02-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT03438279

Locations: 🇺🇸
Local Institution, Boston, Massachusetts, United States

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Other: Placebo

First Posted Date: 2018-02-12

Last Posted Date: 2019-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 112

Registration Number: NCT03429933

Locations: 🇬🇧
Local Institution, London, United Kingdom

A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B

Completed

Conditions: Hepatitis B

Interventions: Other: Non-interventional

First Posted Date: 2018-02-08

Last Posted Date: 2019-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1

Registration Number: NCT03426618

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)

Completed

Conditions: Lung Cancer

First Posted Date: 2018-02-08

Last Posted Date: 2022-01-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 764

Registration Number: NCT03425825

Locations: 🇬🇧
Local Institution, London, United Kingdom

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Phase 2

Completed

Conditions: Hepatic Cirrhosis
Liver Fibrosis

Interventions: Other: Placebo
Drug: BMS-986263

First Posted Date: 2018-02-05

Last Posted Date: 2022-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT03420768

Locations: 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy